Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
Form Type:
Zero Holdings:
Publication Time:
2019-07-12 16:04:43
Reporting Period:
Accepted Time:
2019-07-12 16:04:43
SEC Url:
Form 4 Filing
Cik Name Symbol Sector (SIC) IRS No
1422143 Kura Oncology Inc. KURA Pharmaceutical Preparations (2834) 611547851
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1635794 Antonio Gualberto C/o Kura Oncology, Inc.
3033 Science Park Road, Suite 220
San Diego CA 92121
Head Of Development & Cmo No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2019-07-10 18,000 $6.15 357,973 No 4 M Direct
Common Stock Disposition 2019-07-10 18,000 $21.11 339,973 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Option to purchase common stock Disposition 2019-07-10 18,000 $0.00 18,000 $6.15
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
151,000 2027-01-22 No 4 M Direct
  1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 12, 2019.
  2. This transaction was executed in multiple trades at prices ranging from $21.10 to $21.12. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected
  3. This option vests in 48 equal monthly installments commencing on the grant date.